cyclosporin and methotrexate

PreclinicalSmall molecule

cyclosporin and methotrexate is one of 9 small molecule programs targeting Methotrexate. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MethotrexateCompleted

MethotrexatePreclinical

Completed

Competition

Competitive Landscape

9 competitors in Methotrexate

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Approved

48 2

Xeljanz

PPrism Pharmaceuticals

Approved

3 3

Jaypirca

Eli Lilly

Phase 2

1 4

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 2

2 5

Bavencio

EMD Serono

Phase 2

1 6

Neoral

Novartis

Phase 1

1 7

Rifampicin

Boehringer Ingelheim

Phase 1

2 8

PRX-115

PProtalix

Phase 2

1 9

cyclosporin and methotrexate

GGeorgetown University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Methotrexate1 trial

Low Dose Cyclosporin and Methotrexate Therapy in Diabetes

Completed·GGeorgetown University·N/A·NCT00905073·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for cyclosporin and methotrexate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cyclosporin and methotrexate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cyclosporin and methotrexate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Georgetown University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGeorgetown University

cyclosporin and methotrexate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Methotrexate1 trial

References

Drug Info

Quick Facts

Related News